N4 Pharma PLC (LSE:N4P) - Share price


Stock Report

N4 Pharma PLC N4P

Last Price
GBX8.40

Day Change
0.00|0.00%

As of 17/09/2021
15:10:09 BST | GBX
Minimum 15 Minutes Delay.

Last Close8.40p
Day Range8.30 - 8.45
Mkt Cap15.21Mil
52-Wk Range4.43 - 15.00
Yield %-
ISINGB00BYW8QM32
Volume811,698
P/E-
P/SInfinity
P/CF-0.08

Share Price

Total Returns 17/09/2021

 Chg (%)  
More ...
N4 Pharma PLC-9.19 
FTSE 100 TR GBP-2.51
 
Financials
201820192020
More ...
Income Statement
Turnover-0.000.00
Operating Profit-1.42-0.95-1.56
Net Profit-1.19-0.88-1.31
Reported EPS-1.32-0.87-0.96
Balance Sheet
Current Assets1.071.073.83
Non Current Assets0.000.000.00
Total Assets1.071.073.83
Current Liabilities0.190.080.17
Total Liabilities---
Total Equity0.880.993.66
Cash Flow
Operating Cash Flow-1.42-1.03-1.50
Net Change in Cash-0.530.172.59

Regulatory News

DateAuthor Headline
13/09/2021James Gard Top FTSE Dividend Paying Stocks
UPDATED September 2021: Reshuffle at the top after share price weakness among big names like HSBC
06/09/2021James Gard Stock of the Week: All Posts
Every week we ask our Twitter followers which stocks we should write about - previous winners include Tesla, Amazon and Apple
24/11/2020Damien Conover Covid Vaccine Breakthrough: the Morningstar View
Morningstar analyst Damien Conover looks in detail at the latest vaccine developments from AstraZeneca and Pfizer/BioNTech

Company Profile

N4 Pharma PLC is a United Kingdom-based specialist pharmaceutical company. The company is engaged in reformulating existing drugs and vaccines to improve their performance to benefit the patients. The group operates in one business segment, that of the development and commercialization of medicines via its delivery system called Nuvec.

Sector

Drug Manufacturers - Specialty & Generic

Index

FTSE AIM All-Share

Next Event 24/09/2021

Half-Yearly Results
Ratios
Comp
More ...
PER (E)0.00
Div Yld (E)0.00
PEG (E)0.00
ROCE-42.78
Op Mrgn0.00
EPS Grwth0.00
Dividends
PreviousLatest
More ...
Record Date12/11/9623/05/97
Ex-Div04/11/9619/05/97
Paid02/12/9601/07/97
Amnt17.2018.00
Directors
More ...
Non-Executive Director, ChairmanDr. John Chiplin
Executive DirectorMr. Luke Sebastian Cairns
Executive Director, Chief Executive OfficerMr. Nigel Theobald
Executive DirectorMr. David Templeton
Non-Executive DirectorDr. Christopher Jonathan Britten
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2021 Morningstar. All rights reserved.